logo

Fairs

Fair calendar
2024

feria
DCAT WEEK, NEW YORK18 - 21Mar, 2024Suite #1211
BIO-EUROPE SPRING, BARCELONA18 - 20March, 2024VISITORS
CPHI, TOKYO, JAPAN17 - 19April, 2024VISITORS
CPHI, NORTH AMERICA7 - 9May, 2024VISITORS
CPHI CHINA19 - 21

June, 2024

EXHIBITORS at Stand E1A32
CPHI ASIA, THAILAND10 - 12

July, 2024

EXHIBITORS at Stand M36
CHEMOUTSOURCING4 - 6

September, 2024

EXHIBITORS at Stand 62
CPHI EUROPE, MILAN8 - 10October, 2024EXHIBITORS at Hall 4, 4A33
CPHI INDIA26 - 28November, 2024ATTENDING
CPHI MIDDLE EAST10 - 12December, 2024EXHIBITORS at Stand 1A73
CPHI FRANKFURT28 - 30October, 2025EXHIBITORS at Stand 11.0C6

Contact with us  to settle a meeting

logo
Twitter Linkedin-in
  • Headquarters:
  • Pol. Ind. Cova Solera
  • c/Roma, 8-12 08191 Rubí.
  • Barcelona (Spain)
  • T +34 93 586 05 20
  • Fax +34 93 588 85 13
  • info@moehs.es

Partnering companies

The Board of Directors of the Center for Technological Development and Innovation, E.P.E (CDTI), in its meeting held on 02/23/2023, approved the participation of this center in the research and development project called SYNTHESIS OF A STIMULATOR ACTIVE PRINCIPLE OF SOLUBLE CYCLASE GUANYLATE by granting partially reimbursable aid.

The objective is focused on the development of a new method of chemical synthesis of an active ingredient that stimulates soluble guanylate cyclase.

The project will be carried out at the Rubí facilities. The project execution period is from 2022 to 2024 and they have a financeable budget of €1,862,213.00.
This project is co-financed by the European Union and CDTI.

The Board of Directors of the Center for Technological Development and Innovation, E.P.E (CDTI), in its meeting held on 02/23/2023, approved the participation of this center in the research and development project called SYNTHESIS OF AN ACTIVE INHIBITOR PRINCIPLE OF JANUS KINASE FOR THE TREATMENT OF ATOPIC DERMATITIS.”, by granting partially reimbursable aid.

The objective is focused on the development of a new method of chemical synthesis of a janus kinase inhibitor active ingredient for the treatment of atopic dermatitis.

The project will be carried out at the Rubí facilities. The project execution period is from 2022 to 2025 and they have a financeable budget of €1,940,409.
This project is co-financed by the European Union and CDTI.